Doctors Revision

Neurological System

Nodding Disease

An unexplained neurological condition primarily affecting children (5-15 years), characterized by episodes of repetitive head nodding (atonic seizures), often triggered by food or cold, and associated with cognitive decline, neurological deterioration, and stunted growth.

Also known as: Nodding Syndrome

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer to specialist care (Pediatric Neurologist if available, H/RR/NR) for confirmation of diagnosis, initiation and management of AEDs, and comprehensive supportive care planning.

Red flags

  • Onset of characteristic nodding seizures
  • Progressive cognitive decline
  • Failure to thrive / Stunted growth
  • Frequent uncontrolled seizures

Signs and symptoms

  • Onset typically age 5-7 years in previously normal child.
  • Early symptoms: Problems with concentration and thinking.
  • Characteristic 'nodding' episodes: Repetitive, involuntary dropping forward of the head (atonic seizures).
  • Nodding often triggered by sight/smell of food or cold temperatures.
  • Other seizure types may occur (convulsions, staring spells).
  • Progressive cognitive impairment.
  • Neurological deterioration.
  • Stunted growth and delayed puberty.
  • Physical disability in later stages.

Risk factors

  • Geographical association: Northern Uganda, South Sudan, Southern Tanzania.
  • Strong association with Onchocerca volvulus infection (onchocerciasis, river blindness).
  • Malnutrition (possibly contributing).
  • Pyridoxine (Vitamin B6) deficiency (possibly associated).

Diagnosis

Clinical assessment

Diagnosis based on characteristic clinical features (age of onset, typical nodding seizures triggered by specific stimuli, progressive decline) in a child from an endemic area. Exclusion of other neurological conditions.

Investigations

  • No specific diagnostic test identified.
  • Investigations focus on ruling out other causes and managing associated conditions.
  • Testing for Onchocerciasis (e.g., skin snips - may support association but not diagnostic for nodding disease itself).
  • Nutritional assessment.
  • EEG may show seizure activity but is non-specific.

Diagnostic criteria

Clinical diagnosis based on characteristic syndrome in endemic setting after excluding alternatives. Consistent association with onchocerciasis.

Management

Non-pharmacological management

  • Supportive care is mainstay.
  • Nutritional rehabilitation.
  • Physical and occupational therapy.
  • Psychosocial support for child and family.
  • Management of associated disabilities.

Pharmacological treatment

  • Anti-epileptic drugs (AEDs): To control seizures (nodding and others). Sodium Valproate and Phenobarbital mentioned in UCG. Dose as per standard epilepsy guidelines (Refer to NEU001).
  • Treatment for Onchocerciasis (Ivermectin): Part of community-based control programs in endemic areas, may be relevant due to association.
  • Vitamin supplementation (e.g., Pyridoxine) may be considered.

Monitoring

Monitor seizure frequency and control. Monitor nutritional status and growth. Monitor cognitive and functional status. Assess impact on quality of life.

Complications

  • Severe cognitive impairment
  • Physical disability and dependence
  • Malnutrition and growth failure
  • Injuries related to seizures (falls, burns)
  • Social stigma and exclusion

Prevention

  • Prevention strategies focus on controlling the associated factor, Onchocerciasis, through mass drug administration (Ivermectin) and vector control (black fly) in endemic areas.
  • Improved nutrition.

Patient education

  • Explain the nature of the condition (as understood) to caregivers.
  • Importance of supportive care (nutrition, safety during seizures).
  • Necessity of adherence to AEDs.
  • Address stigma and provide linkage to support services if available.

Uganda-specific notes

Nodding disease has significantly affected specific districts in Northern Uganda. The link to Onchocerciasis is strong, emphasizing the importance of river blindness control programs. Management focuses on seizure control and supportive care within resource limitations.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 9, Section 9.1.2

Scroll to Top